1. Scrip

DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck's REVEAL Genetic Analysis

 
• By Emily Hayes

Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.

Cholesteryl ester transfer protein (3d structure) with a potential use in atherosclerosis therapy. It facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. - Illustration
Three-dimensional illustration of cholesteryl ester transfer protein (CETP), which facilitates the transport of cholesteryl esters and triglycerides between lipoproteins.

DalCor Pharmaceuticals says it's still confident about its dal-GenE outcomes study of genetically selected patients treated with the cholesterol-modulating CETP inhibitor dalcetrapib, but the odds on its big gamble are arguably worsening after a new analysis of Merck & Co. Inc.'s REVEAL outcomes study of anacetrapib did not support the hypothesis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D